CardioDynamics' CEO and President Awarded Ernst & Young's 2003 Entrepreneur of the Year in San Diego.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--June 18, 2003 Michael Perry The name Michael Perry may mean:
and Leadership CardioDynamics (Nasdaq:CDIC CDIC Chronic Diseases In Canada (journal) CDIC Canadian Deposit Insurance Corporation CDIC Carbon Dioxide Information Center CDIC Center for Data Intensive Computing (BNL) ), the innovator and leader of Impedance Cardiography Impedance cardiography is a hemorheology technique of using sensors to detect the properties of the blood flow in the Thorax. Introduction Impedance cardiography (ICG), also referred to as thoracic electrical bioimpedance (TEB) and electrical impedance plethysmography (ICG ICG indocyanine green. ) technology and manufacturer of BioZ(R) noninvasive cardiac function monitoring systems, today announced that the Company's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Michael K. Perry, and President, Rhonda F. Rhyne, were named Ernst & Young's 2003 San Diego's Entrepreneur of the Year(R) in the medical products and technology category. The award recognizes entrepreneurs who have demonstrated outstanding success in the areas of innovation, financial performance, and personal commitment to their businesses and communities. Previous Entrepreneur of the Year award winners include a virtual "Who's Who" of business leaders, including Michael Dell of Dell Computer Corporation (company) Dell Computer Corporation - One of the biggest US manufacturers of IBM PC compatibles. "From notebooks to networks", their slogan says. http://us.dell.com. , Irwin Jacobs of Qualcomm Incorporated, Jim McCann of 1-800-Flowers.com, Steve Case of America Online, Howard Schultz of Starbucks Coffee, and Scott Kriens of Juniper Networks. "It is an honor to accept this award on behalf of CardioDynamics' exceptional team," stated Michael K. Perry, CEO of CardioDynamics. "This award is a true recognition of all the hard work and dedication put forth by every employee of our Company. With over 1.5 million patients monitored, our ICG technology is making a genuine contribution to healthcare. We share this award with our loyal customers and shareholders -- we would not have realized this level of success without them." Under Perry and Rhyne's leadership, CardioDynamics has grown tenfold in the last four years. The Company is ranked by Deloitte & Touche as the 103rd fastest growing technology company in North America. The Company's breakthrough ICG technology provides physicians noninvasive and cost-effective access to vital data about the heart's ability to deliver blood to the body. The information provided by the Company's BioZ(R) heart monitors is helping physicians around the world battle the number one killer of men and women -- cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . About CardioDynamics: CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). Partners include GE Medical Systems Information Technologies, Philips Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the Company's Web site at www.cdic.com. Forward-Looking (Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. ) Statement: Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, such as estimated cardiovascular and ICG industry prospects, market size, potential, growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2002 Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . The Company does not undertake to update the disclosures contained in this press release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion